Essential website updates between 07:00-07:15am CET 13 December 2024 may cause disruption.
Learn more
FOCUS AREAS African Vaccine Manufacturing Accelerator (AVMA) Zero-Dose Child Gavi Secretariat and leadership Progress report Partners Our Board
CAREERS Current vacancies Internship programme RFPs and consulting
Contact us ISO certification Phishing and fraud
SUPPORTED COUNTRIESDetailed information on each Gavi-eligible countryExplore our Country Hub
FOR COUNTRIES
Apply for support
Gavi 5.0 Ceilings by country and support type
OUR RESULTS
Evaluation studies
Facts and figures
Progress reports
African Vaccine Manufacturing Accelerator (AVMA)
COVID-19
#FOROURFUTURE
Five years to save 8 million lives: everything you need to know about Gavi’s Investment Opportunity
Read article
KEY AREAS
Donor profiles
Matching Fund
Pneumococcal AMC
SPOTLIGHT ON REACHING THE UNIMMUNISED
KEY PUBLICATION
Investment Opportunity 2026–2030Download
LATEST
Progress report
News releases
Communication toolkits
MenAfriVac, a new vaccine against Meningococcal Meningitis seroptype Nm A, is expected to prevent meningitis epidemics in Africa's "meningitis belt" of 25 countries that stretch from Senegal in the west to Ethiopia in the east.
